Search This Blog

Wednesday, August 11, 2021

CohBar: Positive Topline Results in Phase 1a/1b Study of CB4211 for NASH and Obesity

 

  • CB4211 was well-tolerated and appeared safe with no serious adverse events

  • Robust reductions in ALT and AST

  • Reduction in glucose and trend towards body weight reduction

  • Company to host conference call and webcast

Conference Call:

Date: August 10, 2021
Time: 5:00 p.m. ET (2:00 p.m. PT)

Conference Audio

  • Dial-in U.S. and Canada: (877) 300-8521

  • Dial-in International: (412) 317-6026

  • Conference ID No.: 10159293

Slide Presentation

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.